Mon 08 Feb 2010 |
|
Tuesday, 09 February 2010 12:38
|
|
| | Street Shot is a health promotion initiative using photography to raise awareness about hepatitis C-related issues amongst young people. Young people who are engaged with youth services and alternative education settings will be provided with education and support to learn about hepatitis C and take photos to reflect these issues.
This project was first developed by the Hepatitis C Council of NSW and was highly successful. To hear about the experiences from young people, participating agencies and the Hepatitis C Council of NSW check out this 5 minute video on YouTube. http://www.youtube.com/watch?v=r9IdjyOdJoA
We encourage you to get involved in this exciting project. For further information, see the flier - http://www.hepcvic.org.au/pdf/Street%20Shot%20flyer.pdf or email Emily Lenton
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Expressions of Interest need to be in by the 12th of February - so hurry! |
|
Sun 07 Feb 2010 |
|
Tuesday, 09 February 2010 12:38
|
|
| | Welcome to the home page for the Australasian Viral Hepatitis Conference 2010 to be held from 6 - 8 September at Sebel Albert Park, Melbourne, Victoria. The conference theme is Looking Back, Moving Forward: Challenges for the Next Decade.
Please mark these dates in your diary and share this information with colleagues.
Dates for your Diary Abstract Submission Deadline - 23rd April 2010 Scholarship Application Deadline - 23rd April 2010 Early Bird Registration Deadline - 2nd July 2010 Accommodation Booking Deadline - 30th July 2010 Standard Registration Deadline - 26th August 2010 Conference Dates - 6th to 8th September 2010
|
Thu 04 Feb 2010 |
|
Tuesday, 09 February 2010 12:38
|
|
| | By Liz Highleyman
Drugs that attack the hepatitis C virus (HCV) directly—dubbed specifically-targeted antiviral therapy for hepatitis C, or “STAT-C”—represent a paradigm shift in the management of the disease.
The current standard of care for chronic hepatitis C treatment, pegylated interferon plus ribavirin, works by stimulating the body’s immune response against the virus. Interferons are natural chemical messengers (cytokines) that regulate immune function. Ribavirin, an IMPDH inhibitor (Inosine monophosphate dehydrogenase), has the ability to inhibit viral replication by interfering with ribonucleic acid (RNA) production, but in practice appears to work primarily as an immune modulator.
Several new anti-HCV drugs now in development work another way—by blocking or interfering with specific steps in viral replication. In order to understand the potential of these novel agents, it is useful to look at the HCV life cycle and various ways it can be disrupted.
|
Wed 27 Jan 2010 |
|
Tuesday, 09 February 2010 12:38
|
|
| | (RTTNews) - Achillion Pharmaceuticals Inc. ( ACHN | Quote | Chart | News | PowerRating) is scheduled to host a Corporate and Clinical Update conference call on Monday, February 1, highlighting the company's progress in its pipeline of HCV drugs. The company will also provide an update on its partnering efforts related to its antibiotic candidate ACH-702 as well as its HIV product candidate Elvucitabine.
Achillion's product pipeline includes ACH-1625 and ACH-1095 for the treatment of chronic hepatitis C infection; ACH-702 for the treatment of serious, resistant bacterial infections and Elvucitabine for the treatment of HIV.
ACH-1625, a potent HCV inhibitor, is under phase I study. The preliminary results of a phase Ib study of ACH-1625 reported early this month showed that there is a dramatic reduction in viral load after 5 days of monotherapy and continued suppression of viral load after drug discontinuation.
|
Wed 27 Jan 2010 |
|
Tuesday, 09 February 2010 12:38
|
|
| | Howard Hughes Medical Institute researchers and their colleagues at the Rockefeller University have developed a new method for growing human liver cells outside the body. Using the new cell culture system, scientists can now study hepatitis C virus in the lab over a period of weeks – which may boost efforts to develop a vaccine or broadly effective treatment for the infection. Until now, scientists working on hepatitis C vaccine design have been hampered by the lack of an animal model or a culture system that could support long-term study of viral infection.
|
|
|
|
|